March 3, 2017

Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting

- Additional Presentation Affirms Use of Patient Questionnaires in Assessing Frown Lines -

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the company's BELMONT Phase 2 study of DaxibotulinumtoxinA Injectable (RT002) at the 2017 American Academy of Dermatology (AAD) Annual Meeting, taking place at the Orange County Convention Center in Orlando, Florida, March 3-7, 2017. BELMONT was the company's Phase 2 active comparator, placebo-controlled, multi-center study to evaluate the safety, efficacy, and duration of effect of RT002 injectable for the treatment of glabellar (frown) lines, the 24-week results of which were reported in October 2015. Findings from a patient's perspective study also being reported at the AAD annual meeting confirm the content validity of patient questionnaires in measuring the impact of frown lines.

Scheduled data presentations at 2017 AAD Annual Meeting:

Poster Presentation: *"Duration and Onset of Glabellar Frown Line Reduction after an Injection of DaxibotulinumtoxinA: Results of the BELMONT Study", March 3, 1:30 PM to 1:35 PM ET, Orlando, Florida*

A poster highlights final data from the BELMONT Phase 2 active comparator and placebo-controlled study of RT002 injectable for the treatment of moderate to severe glabellar lines in adults.

Poster Presentation: *"Impacts of Glabellar Facial Lines - A Patient Perspective", March 3, 2:15 PM to 2:20 PM ET, Orlando, Florida*

A second poster reports on findings validating the Patient Frown Wrinkle Severity (PFWS) assessment, currently being used in Revance's SAKURA Phase 3 clinical program, and two recently developed questionnaires, the Frown Line Impact Scale (FLIS) and the Facial Age Self Evaluation (FASE) scale.

"Physician interest continues to mount for our BELMONT results, and AAD provides an important opportunity to showcase our differentiated clinical findings, including increased response rates and extended duration of effect of RT002 compared to the market-leading neurotoxin," said Dan Browne, President and Chief Executive Officer at Revance. "A content validity study also examines our innovation of clinical assessment tools, further underscoring our commitment to delineate the patient experience and outcomes."

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary peptide technology platform. More information on Revance may be found at www.revance.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the process and timing of, and

ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and statements about our ability to obtain regulatory approval; and potential benefits of our drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risks that interim results are not indicative of final results and that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" of our annual report on Form 10-K filed February 28, 2017. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170303005166/en/

Investors:
Revance Therapeutics, Inc.
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.